See more : Yincheng International Holding Co., Ltd. (1902.HK) Income Statement Analysis – Financial Results
Complete financial analysis of NanoVibronix, Inc. (NAOV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NanoVibronix, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- APA Group (APA.AX) Income Statement Analysis – Financial Results
- Vinte Viviendas Integrales, S.A.B. de C.V. (VINTE.MX) Income Statement Analysis – Financial Results
- The Kroger Co. (0JS2.L) Income Statement Analysis – Financial Results
- Libord Securities Limited (LIBORD.BO) Income Statement Analysis – Financial Results
- Medifast, Inc. (MED) Income Statement Analysis – Financial Results
NanoVibronix, Inc. (NAOV)
About NanoVibronix, Inc.
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.28M | 752.00K | 1.70M | 623.00K | 530.00K | 318.00K | 239.00K | 229.00K | 147.00K | 203.00K | 211.00K | 166.00K | 94.00K |
| Cost of Revenue | 746.00K | 585.00K | 925.00K | 409.00K | 249.00K | 158.00K | 88.00K | 88.00K | 49.00K | 93.00K | 91.00K | 50.00K | 29.00K |
| Gross Profit | 1.54M | 167.00K | 770.00K | 214.00K | 281.00K | 160.00K | 151.00K | 141.00K | 98.00K | 110.00K | 120.00K | 116.00K | 65.00K |
| Gross Profit Ratio | 67.32% | 22.21% | 45.43% | 34.35% | 53.02% | 50.31% | 63.18% | 61.57% | 66.67% | 54.19% | 56.87% | 69.88% | 69.15% |
| Research & Development | 185.00K | 283.00K | 293.00K | 171.00K | 514.00K | 614.00K | 693.00K | 584.00K | 399.00K | 431.00K | 620.00K | 572.00K | 510.00K |
| General & Administrative | 3.92M | 3.93M | 5.06M | 3.77M | 3.82M | 2.64M | 2.08M | 1.36M | 747.00K | 589.00K | 366.00K | 128.00K | 87.00K |
| Selling & Marketing | 864.00K | 965.00K | 1.10M | 993.00K | 1.10M | 1.21M | 465.00K | 514.00K | 377.00K | 301.00K | 244.00K | 190.00K | 150.00K |
| SG&A | 4.79M | 4.90M | 6.16M | 4.76M | 4.92M | 3.85M | 2.55M | 1.87M | 1.12M | 890.00K | 610.00K | 318.00K | 237.00K |
| Other Expenses | 0.00 | 0.00 | -1.63M | 42.00K | -412.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.00K | 0.00 | 0.00 |
| Operating Expenses | 4.97M | 5.18M | 6.45M | 4.93M | 5.43M | 4.46M | 3.24M | 2.46M | 1.52M | 1.32M | 1.23M | 890.00K | 747.00K |
| Cost & Expenses | 5.72M | 5.76M | 7.38M | 5.34M | 5.68M | 4.62M | 3.33M | 2.55M | 1.57M | 1.41M | 1.32M | 940.00K | 776.00K |
| Interest Income | 0.00 | 54.00K | 48.00K | 147.00K | 15.00K | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 | 1.00K | 1.00K |
| Interest Expense | 246.00K | 347.00K | 0.00 | 147.00K | 62.00K | 22.00K | 1.23M | 0.00 | 65.00K | 372.00K | 782.00K | 256.00K | 21.00K |
| Depreciation & Amortization | 1.00K | 1.00K | 2.00K | 2.00K | 4.00K | 6.00K | 5.00K | 7.00K | 9.00K | 9.00K | 10.00K | 9.00K | 10.00K |
| EBITDA | -3.44M | -5.01M | -14.25M | -4.16M | -5.75M | -4.28M | -3.64M | -2.69M | -2.38M | -1.33M | -1.23M | -1.01M | -692.00K |
| EBITDA Ratio | -150.46% | -673.54% | -433.98% | -757.14% | -1,048.87% | -1,344.34% | -1,313.39% | -1,014.85% | -1,238.10% | -1,024.14% | -771.56% | -608.43% | -736.17% |
| Operating Income | -3.44M | -5.01M | -5.68M | -4.72M | -5.15M | -4.30M | -3.09M | -2.32M | -1.42M | -1.21M | -1.11M | -774.00K | -682.00K |
| Operating Income Ratio | -150.50% | -666.49% | -335.28% | -757.46% | -971.89% | -1,353.14% | -1,293.31% | -1,011.35% | -968.71% | -596.55% | -526.07% | -466.27% | -725.53% |
| Total Other Income/Expenses | -246.00K | -401.00K | -8.57M | 408.00K | -660.00K | 22.00K | -1.84M | -398.00K | -1.43M | -1.39M | -844.00K | -501.00K | -41.00K |
| Income Before Tax | -3.68M | -5.41M | -14.25M | -4.31M | -5.81M | -4.28M | -4.93M | -2.71M | -2.86M | -2.60M | -1.95M | -1.28M | -723.00K |
| Income Before Tax Ratio | -161.28% | -719.81% | -840.71% | -691.97% | -1,096.42% | -1,346.23% | -2,061.51% | -1,185.15% | -1,942.86% | -1,279.80% | -926.07% | -768.07% | -769.15% |
| Income Tax Expense | 29.00K | 35.00K | 32.00K | 15.00K | -17.00K | -127.00K | 38.00K | 117.00K | 28.00K | 49.00K | 35.00K | 10.00K | -20.00K |
| Net Income | -3.71M | -5.45M | -14.28M | -4.33M | -5.79M | -4.15M | -4.97M | -2.83M | -2.88M | -2.65M | -1.99M | -1.28M | -723.00K |
| Net Income Ratio | -162.55% | -724.47% | -842.60% | -694.38% | -1,093.21% | -1,306.29% | -2,077.41% | -1,236.24% | -1,961.90% | -1,303.94% | -942.65% | -768.07% | -769.15% |
| EPS | -2.12 | -3.84 | -11.35 | -8.40 | -16.70 | -12.88 | -20.00 | -12.37 | -16.31 | -20.27 | -15.23 | -9.77 | -5.54 |
| EPS Diluted | -2.12 | -3.84 | -11.35 | -8.40 | -16.70 | -12.88 | -20.00 | -12.37 | -16.31 | -20.27 | -15.23 | -9.77 | -5.54 |
| Weighted Avg Shares Out | 1.75M | 1.42M | 1.26M | 514.91K | 346.97K | 322.42K | 248.20K | 228.92K | 176.82K | 130.57K | 130.57K | 130.57K | 130.57K |
| Weighted Avg Shares Out (Dil) | 1.75M | 1.42M | 1.26M | 514.91K | 346.97K | 322.42K | 248.20K | 228.92K | 176.82K | 130.57K | 130.57K | 130.57K | 130.57K |
NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its PainShield® MD PLUS, its dual-actuator...
NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus
ELMSFORD, N.Y.--( BUSINESS WIRE )--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its PainShield® MD PLUS,...
NanoVibronix Announces Interim Results of Clinical Study for UroShield
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced interim results of its U.K. clinical study for UroShield that is being conducted by The...
NanoVibronix Announces Interim Results of Clinical Study for UroShield
ELMSFORD, N.Y.--( BUSINESS WIRE )-- NanoVibronix, Inc ., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced interim results of its U.K. clinical study for UroShield that is...
NanoVibronix Provides Business Update in Letter to Shareholders
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided the following business update in a letter to shareholders from its Chief Executive Officer, Brian...
NanoVibronix Provides Business Update in Letter to Shareholders
ELMSFORD, N.Y.--( BUSINESS WIRE )-- NanoVibronix, Inc. , (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided the following business update in a letter to shareholders from its...
NanoVibronix Receives Extension to Satisfy Nasdaq Price Requirement
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that on October 17, 2022, a Nasdaq Hearings Panel (the “Panel”) granted the Company’s request...
Long Term Penny Stocks Investing Strategy (Complete Guide)
Use this guide for investing in penny stocks in the long term The post Long Term Penny Stocks Investing Strategy (Complete Guide) appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
NanoVibronix UroShield Approved for Sale through NHS Internal Supply Chain Contract
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced its UroShield has been approved for sale by the U.K.’s National Health System’s (NHS) internal...
Source: https://incomestatements.info
Category: Stock Reports